What development phase is Celtect in?

Celtect is FDA-approved (marketed).

What is the generic name of Celtect?

OXATOMIDE is the generic (nonproprietary) name of Celtect.

Last reviewed 2026-04-20 · How we verify

Celtect (OXATOMIDE)

FDA-approved active Small molecule Quality 10/100

OXATOMIDE (Celtect) is a marketed antihistamine that binds to the 5-hydroxytryptamine receptor 2B, currently positioned in a competitive landscape with several same-class drugs. Its key strength lies in its unique mechanism of action targeting the 5-HT2B receptor, which may offer distinct therapeutic benefits over traditional antihistamines. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	OXATOMIDE
Drug class	oxatomide
Target	P2X purinoceptor 7, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B
Modality	Small molecule
Therapeutic area	Hematology
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

KUL0401: An Open-label Pilot Study of Oxatomide in Steroid-Naive Duchenne Muscular Dystrophy (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Celtect CI brief — competitive landscape report
Celtect updates RSS · CI watch RSS